Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China

Jieqiong Zhou, Gang An, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 8142.

https://doi.org/10.1182/blood-2025-8142

Published: 2025

Journal Articles

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

Gang An, Jieqiong Zhou, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2025-2246

Published: 2025

Journal Articles

Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death

Jiye Liu, Jingyu Xu, Teru Hideshima, Kenneth Wen, Yuntong Liu, Nikhil Munshi, Lijie Xing, Gang An, Kenneth Anderson

Blood (2025) 146 (Supplement 1): 2153.

https://doi.org/10.1182/blood-2025-2153

Published: 2025

Journal Articles

The unique role of PSMD2/Rpn1 among ubiquitin receptors in multiple myeloma highlights its potential as a therapeutic target to overcome proteasome inhibitor resistance

Ting Du, Yuntong Liu, Minxing Wang, Teng Fang, Jingyu Xu, Kenneth Wen, Xueping Wan, Arghya Ray, Sindhu Pillai, Md Abu Musa, Mariateresa Fulciniti, Nikhil Munshi, Yan Song, Kenneth Anderson

Blood (2025) 146 (Supplement 1): 2148.

https://doi.org/10.1182/blood-2025-2148

Published: 2025

Journal Articles

Dynamic changes in cytogenetic abnormalities during treatment predict long-term outcomes in multiple myeloma

Jieqiong Zhou, Yuntong Liu, Gang An, Lugui Qiu

Blood (2025) 146 (Supplement 1): 7542.

https://doi.org/10.1182/blood-2025-7542

Published: 2025

Journal Articles

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

Yating Li, Yuntong Liu, Jieqiong Zhou, Wenqiang Yan, Jian Cui, Jingyu Xu, Chenxing Du, Shuhui Deng, Yan Xu, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 5761.

https://doi.org/10.1182/blood-2025-5761

Published: 2025

Journal Articles

In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China

Jieqiong Zhou, Gang An, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 7550.

https://doi.org/10.1182/blood-2025-7550

Published: 2025

Journal Articles

CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.

Yuntong Liu, Weiwei Sui, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 4068.

https://doi.org/10.1182/blood-2025-4068

Published: 2025

Journal Articles

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

Jingyu Xu, Qirui Bai, Yuntong Liu, Wenqiang Yan, Shuaishuai Zhang, Wenyang Huang, Chenxing Du, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2025-4067

Published: 2025

Journal Articles

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Yuntong Liu, Weiwei Sui, Rui Lyu, Chenxing DU, Shuaishuai Zhang, Tengteng Yu, Jingyu Xu, Wenqiang Yan, Yuting Yan, Wei Liu, Yi Wang, Qi Wang, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2024-200117

Published: 2024

Journal Articles

T(11;14) with Multiple Myeloma: Standard Risk Survival but Slow and Poor Response

Yuntong Liu, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2024-200904

Published: 2024

Journal Articles

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Jingyu Xu, Yuntong Liu, Wenqiang Yan, Lingna Li, Rui Lyu, Chenxing DU, Weiwei Sui, Lugui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 6917.

https://doi.org/10.1182/blood-2024-201167

Published: 2024

Journal Articles

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Jingyu Xu, Shuaishuai Zhang, Wenqiang Yan, Yuntong Liu, Rui Lyu, Chenxing DU, Weiwei Sui, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2024-200847

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death

The unique role of PSMD2/Rpn1 among ubiquitin receptors in multiple myeloma highlights its potential as a therapeutic target to overcome proteasome inhibitor resistance

Dynamic changes in cytogenetic abnormalities during treatment predict long-term outcomes in multiple myeloma

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China

CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

T(11;14) with Multiple Myeloma: Standard Risk Survival but Slow and Poor Response

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only